News
The popularity of GLP-1 drugs has insurance companies scrambling to satisfy consumer access while reining in exorbitant costs ...
Though Eli Lilly and Novo Nordisk have recently taken steps to make their uber-popular GLP-1 drugs more affordable for ...
Novo Nordisk boosts Wegovy access with discounts as FDA bans compounded semaglutide drugs and cracks down on weight-loss copycats.
Weight loss drugs Ozempic and Wegovy would no longer be covered by California's health insurance for low-income people under ...
Researchers in Spain reported that halving the dose of Novo Nordisk's Wegovy weight-loss drug did not alter results. Participants achieved similar weight loss on reduced doses, signaling potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results